Table 4.

Extracted outcomes from NCPE summary HTA reports

Drug	Comparator	Extracted data			Yeara	Converted to US$
		ICER (€ per QALY)	Incremental costs (€)	Incremental QALYs		ICER (2017 US$)	Incremental costs (2017 US$)
Vemurafenib [31]	Dacarbazine	131,883	NR	NR	2012	177,233	NR
Dabrafenib [30]	Dacarbazine	84,473	113,613	1.35	2014	112,741	151,632
Dabrafenib [30]	Vemurafenib	Dominant	− 43,380	0.36	2014	Dominant	− 57,897
Ipilimumab 2L [27]	BSC	147,899	NR	NR	2011	202,168	NR
Pembrolizumab 1L [28]	Ipilimumab	Dominant	− 3093	0.42	2016	Dominant	− 4140
Pembrolizumab 2L [29]	BSC	85,766	72,280	0.84	2016	114,801	96,749
Nivolumab 1L [34]	Ipilimumab	101,282	NR	NR	2016	135,569	NR
Nivolumab 1L [34]	Vemurafenib	29,018	NR	NR	2016	38,842	NR
Nivolumab 1L [34]	Dabrafenib	46,276	NR	NR	2016	61,942	NR
Nivo + Ipi [32]	Ipilimumab	47,748	101,354	2.13	2016	63,912	135,666
Nivo + Ipi [32]	Nivolumab	Dominant	− 7,792	0.93	2016	Dominant	− 10,430
Nivo + Ipi [32]	Pembrolizumab	Dominant	− 143,751	0.94	2016	Dominant	− 192,416
Nivo + Ipi [32]	Dab + Tram	14,850	21,454	1.45	2016	19,877	28,717
Dab + Tram [33]	Vemurafenib	177,275	170,314	0.96	2017	236,367	227,085
Dab + Tram [33]	Dabrafenib	244,822	182,417	0.75	2017	326,429	243,223
Dab + Tram [33]	Pembrolizumab	126,128	56,299	0.45	2017	168,171	75,065
Vem + Cobi [26]	Vemurafenib	326,868	168,266	0.51	2017	435,824	224,355
Vem + Cobi [26]	Dabrafenib	324,192	189,936	0.59	2017	432,256	253,248
Vem + Cobi [26]	Dab + Tram	108,284	15,806	0.15	2017	144,379	21,075

1L first line, 2L second line, BSC best supportive care, Dab + Tram dabrafenib in combination with trametinib, HTA health technology assessment, ICER incremental cost-effectiveness ratio, NCPE National Centre for Pharmacoeconomics, Nivo + Ipi nivolumab in combination with ipilimumab, NR not reported, QALY quality-adjusted life-year, Vem + Cobi vemurafenib in combination with cobimetinib

^aYear of publication on NCPE website